Skip to main contentAI and Advanced
/
STAR · NSEMarket ticker unavailable · configure an authorised index feed
ST
NSE · Equity shares · Biotechnology & Drugs42.80 · 3.73%
Strides Pharma Science STAR
NSE:INR 1,190.8
BSE:INR 999.15
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for STAR
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,148
Day rangeINR 1,102 — INR 1,192
52-week rangeINR 768.65 — INR 1,231
Volume3.98 L
Market cap9,209.44
P/E16.42
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)4,858.68
Net Income (INR Cr)556.19
Rev Growth (5 Year %)7.94
EPS Growth (5 Year %)16.29
P/E Ratio16.42
EPS62.65
Research path: Interpret Strides Pharma Science's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
STARStrides Pharma Science1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 6,927.23 | 6,048.73 | 5,839.76 |
| Accumulated Depreciation Total | -813.51 | -709.05 | -659.74 |
| Cash Equivalents | 5.19 | 4.85 | 72.72 |
| Other Liabilities Total | 157.58 | 128.69 | 105.31 |
| Accrued Expenses | 66.85 | 69.59 | 51.9 |
| Long Term Debt | 552.32 | 571.24 | 671.5 |
| Common Stock Total | 92.17 | 92.16 | 91.9 |
| Other Equity Total | 277.14 | 198.05 | 189.83 |
| Other Current Assets Total | 9.43 | 16.06 | 12.04 |
| Prepaid Expenses | 74.76 | 61.72 | 70.69 |
| Total Assets | 6,927.23 | 6,048.73 | 5,839.76 |
| Current Portof LT Debt/Capital Leases | 114.49 | 120.57 | 199.58 |
| Additional Paid-In Capital | 1,510.1 | 1,509.45 | 1,823.43 |
| Cash | 183.51 | 107.71 | 88.3 |
| Total Equity | 3,107.57 | 2,551.83 | 2,125.56 |
| Long Term Investments | 308.56 | 440.39 | 328.73 |
| Retained Earnings(Accumulated Deficit) | 1,303.93 | 789.48 | 199.78 |
| Total Common Shares Outstanding | 9.22 | 9.22 | 9.19 |
| Property/Plant/Equipment Total-Gross | 1,967.06 | 1,689.38 | 1,618.29 |
| Tangible Book Valueper Share Common Eq | 185.9 | 155.95 | 116.33 |
| Goodwill Net | 594.42 | 546.57 | 529.41 |
| Total Liabilities | 3,819.67 | 3,496.89 | 3,714.19 |
| Total Debt | 1,757.98 | 1,879.63 | 2,516.87 |
| Short Term Investments | 15.79 | 86.06 | 128.54 |
| Cashand Short Term Investments | 204.48 | 198.62 | 289.56 |
| Total Receivables Net | 1,628.21 | 1,512.46 | 1,407.46 |
| Notes Payable/Short Term Debt | 1,039.34 | 1,136.36 | 1,574.15 |
| Deferred Income Tax | 120.67 | 119.36 | 40.35 |
| Accounts Receivable-Trade Net | 1,289.32 | 1,203.18 | 1,146.73 |
| Property/Plant/Equipment Total-Net | 1,153.55 | 980.34 | 958.55 |
| Minority Interest | 41.77 | 34.63 | -53.86 |
| Total Current Liabilities | 2,895.49 | 2,591.52 | 2,879.26 |
| Total Inventory | 1,696.46 | 1,310.04 | 1,189.25 |
| ESOP Debt Guarantee | 0.56 | 0.51 | 2.97 |
| Accounts Payable | 1,309.68 | 1,032.5 | 851.59 |
| Other Currentliabilities Total | 365.13 | 232.5 | 202.04 |
| Total Long Term Debt | 604.16 | 622.7 | 743.13 |
| Intangibles Net | 799.65 | 567.97 | 527.12 |
| Other Long Term Assets Total | 377.1 | 349.16 | 341.12 |
| Note Receivable-Long Term | 80.6 | 65.39 | 185.83 |
| Unrealized Gain(Loss) | -76.33 | -37.82 | -182.35 |
| Total Current Assets | 3,613.34 | 3,098.91 | 2,969 |
| Capital Lease Obligations | 51.84 | 51.46 | 71.64 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.89
Price to Sale Ratio1.90
Growth
Debt 5Yr CAGR %-5.63
Margins
Operating Margin 12m15.42
Operating Margin 5y Avg5.27
Net Profit Margin 12m12.68
Net Profit Margin 5y0.67
Yield
Dividend Yield %0.52
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk31.56
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 27.91%
- FII
- 28.40%
- MF
- 8.73%
- Other
- 34.96%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Strides Pharma Science files BRSR for FY26 - scanx.tradeMarket news · 21 Jul 2026, 4:00 pm
Strides Pharma Science files BRSR for FY26 scanx.trade
Strides Pharma Science fixes July 31 record date for ₹5 dividend - scanx.tradeMarket news · 20 Jul 2026, 1:24 pm
Strides Pharma Science fixes July 31 record date for ₹5 dividend scanx.trade
Strides Brings in Ascent Capital to Drive Next Phase of Growth for Pivot Path - Machine MakerMarket news · 13 Jul 2026, 1:21 pm
Strides Brings in Ascent Capital to Drive Next Phase of Growth for Pivot Path Machine Maker
Price to book forward of Strides Pharma Science Ltd – NSE:STAR - TradingViewMarket news · 12 Jul 2026, 6:37 pm
Price to book forward of Strides Pharma Science Ltd – NSE:STAR TradingView
Strides Pharma Science Share Price - Live NSE: STAR Stock Price & Chart - UpstoxMarket news · 10 Jul 2026, 12:30 pm
Strides Pharma Science Share Price - Live NSE: STAR Stock Price & Chart Upstox
Strides completes sale of Pivot Path stake for ₹1,000 million - scanx.tradeMarket news · 3 Jul 2026, 12:30 pm
Strides completes sale of Pivot Path stake for ₹1,000 million scanx.trade
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.5.0000 per share(50%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Strides Pharma Science
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- STAR
- BSE Code
- 532531
Questions
Stock FAQ
What is the symbol and ISIN of Strides Pharma Science?
Strides Pharma Science has the symbol STAR and ISIN - INE939A01011.
What is the current price of Strides Pharma Science?
Strides Pharma Science is currently trading at INR 1,190.80.
What are the year high and year low of Strides Pharma Science?
Strides Pharma Science has a year high of INR 1,231.00 and a year low of INR 768.65.
What is the market capitalization of Strides Pharma Science?
Strides Pharma Science has a market capitalization of INR 9,209.44 crore.
What is the P/E ratio of Strides Pharma Science?
Strides Pharma Science has a P/E ratio of 16.42.
What is the dividend yield of Strides Pharma Science?
Strides Pharma Science has a dividend yield of 0.52%.
How is the financial performance of Strides Pharma Science based on revenue, net income, and EPS?
Strides Pharma Science has revenue of INR 4,858.68 crore, net income of INR 556.19 crore, and EPS of INR 62.60.
What is the book value of Strides Pharma Science?
Strides Pharma Science has a book value of NA.
What is the debt-to-equity ratio of Strides Pharma Science?
Strides Pharma Science has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Strides Pharma Science?
Strides Pharma Science has a price-to-book ratio of NA and a price-to-sales ratio of 1.90.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.